Uma forma rara de linfoma difuso de grandes células B que ocorre mais comumente em pacientes com mais de 50 anos de idade (geralmente entre 70 e 75 anos de idade), sem imunodeficiência evidente, e que se apresenta com envolvimento nodal e extranodal (em locais como estômago, pulmão, pele e pâncreas) e sintomas B (febre, suores noturnos, perda de peso). O tumor é caracterizado por um curso agressivo e uma taxa de sobrevida curta.
Introdução
O que você precisa saber de cara
Visão geral
O Linfoma B difuso de grandes células positivo para o vírus Epstein-Barr é uma forma rara de linfoma difuso de grandes células B associada ao código CID-10 C83.3. Trata-se de uma condição com prevalência desconhecida, cujo início dos sintomas ocorre tipicamente em adultos e idosos, sendo mais frequente em indivíduos com mais de 50 anos de idade (geralmente entre 70 e 75 anos), sem imunodeficiência evidente.[1]
Sinais e sintomas
O quadro clínico apresenta-se com envolvimento tanto nodal quanto extranodal, atingindo locais como estômago, pulmão, pele e pâncreas. Os pacientes frequentemente manifestam sintomas constitucionais B, caracterizados por febre, suores noturnos e perda de peso.[1]
Causas genéticas
O padrão de herança genética é classificado como não aplicável para esta doença e não há genes causais específicos listados nos registros.[1]
Diagnóstico
Existe registro de 1 teste genético disponível associado à condição nos dados cadastrados.[1]
Tratamento e manejo
No âmbito do Sistema Único de Saúde (SUS), o Protocolo Clínico e Diretrizes Terapêuticas (PCDT) vigente para Linfoma Difuso de Grandes Células B (Portaria SAS/MS nº 956, de 26 de setembro de 2014) prevê a dispensação conforme a autonomia do serviço de saúde.[2]
Prognóstico e qualidade de vida
O tumor é caracterizado por um curso biológico agressivo e está associado a uma taxa de sobrevida curta.[1]
Conteúdo informativo gerado e mantido automaticamente a partir de fontes oficiais (Orphanet, HPO, OMIM, SUS). Não substitui avaliação médica.
O linfoma B difuso de grandes células positivo para o vírus Epstein-Barr é um tipo raro e agressivo de câncer que surge nas células de defesa do organismo. A condição afeta com maior frequência adultos e idosos acima de 50 anos, causando febre, suores noturnos, perda de peso e aumento de gânglios ou alterações em órgãos como estômago e pulmões. No SUS, o tratamento é oferecido conforme a autonomia de cada serviço de oncologia especializado, sob as diretrizes do PCDT de Linfoma Difuso de Grandes Células B. Por ter uma progressão rápida, o diagnóstico ágil e o acompanhamento próximo em centros hospitalares são fundamentais para o paciente.
Uma forma rara de linfoma difuso de grandes células B que ocorre mais comumente em pacientes com mais de 50 anos de idade (geralmente entre 70 e 75 anos de idade), sem imunodeficiência evidente, e que se apresenta com envolvimento nodal e extranodal (em locais como estômago, pulmão, pele e pâncreas) e sintomas B (febre, suores noturnos, perda de peso). O tumor é caracterizado por um curso agressivo e uma taxa de sobrevida curta.
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Nenhum gene associado encontrado
Os dados genéticos desta condição ainda estão sendo catalogados.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Linfoma B difuso de grandes células positivo para o vírus Epstein-Barr
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
Com ensaio aberto em 2 países. O ponto verde marca onde há vaga agora.
🟢 Recrutando agora
1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
9 ensaios clínicos encontrados, 2 ativos.
Publicações mais relevantes
Long noncoding RNA ADEI/miR-93-3p/STAT3 axis promotes Epstein-Barr virus-positive diffuse large B-cell lymphoma progression and immune evasion through regulating the PD-1/PD-L1 checkpoint.
Epstein-Barr virus (EBV) is an important pathogenic factor of lymphoma; EBV+diffuse large B-cell lymphoma (DLBCL) has a worse prognosis with standard chemotherapy than EBV-DLBCL. Long noncoding (Lnc)-RNAs are key regulators of cancer pathways and biomarkers of disease. As natural protective carriers of noncoding RNAs, exosomes can stably transmit signals during tumor development. We explored the role of exosomal lncRNAs in the occurrence and development of EBV-related DLBCL. In this study, we identified a novel lncRNA lncADEI, which was upregulated in EBV + DLBCL and was positively correlated with DLBCL cell proliferation and clonogenesis. LncADEI positively regulated STAT3 via miR-93-3P, and STAT3 transcriptionally activated programmed death ligand-1 to promote immune evasion of DLBCL cells. LncADEI could be transferred by exosomes and promote the proliferation and immune evasion of DLBCL. LncADEI was highly expressed in serum exosomes from EBV + DLBCL patients and was associated with worse clinicopathological features. In conclusion, lncADEI participated in the progression and immune evasion of EBV + DLBCL and was differentially expressed in serumal exosomes. LncADEI may be a promising strategy for treating EBV-associated lymphoid malignancies.
ORY1001 enhances anti-tumor immunity via CXCL10-mediated macrophage modulation in EBV-positive DLBCL.
Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV+ DLBCL) is an aggressive malignancy characterized by an immunosuppressive tumor microenvironment (TME), where tumor-associated macrophages (TAMs) often exhibit an M2-like phenotype that facilitates immune evasion. Here, we show that the LSD1 inhibitor ORY1001 reprograms the TME of EBV+ DLBCL through CXCL10-mediated modulation of macrophage polarization. Using a reductionist model in which EBV-negative DLBCL cell lines were transfected with LMP1, we demonstrate that ORY1001 induces robust expression of CXCL10, TNF-α and IL-6 in LMP1+ Riva cells, promoting M1 macrophage differentiation and reprogramming M2 macrophages toward a pro-inflammatory phenotype. This CXCL10-driven macrophage reprogramming was also observed in an additional LMP1+ DLBCL line (U2932) and in primary EBV+ DLBCL cells, in which ORY1001 selectively increased CXCL10 levels in tumor-cell supernatants, and conditioned media from these cultures—but not direct ORY1001 exposure—drove M1 polarization of THP-1 and primary CD14+ monocytes. These effects were dependent on CXCL10-CXCR3 signaling, as pharmacological inhibition of CXCR3 abrogated M1 polarization. In vivo, ORY1001 suppressed tumor growth in LMP1-expressing A20 lymphoma models, increased CXCL10 levels, and enhanced M1 macrophage infiltration. Furthermore, ORY1001 synergized with anti–PD-1 therapy to enhance T-cell activation, granzyme B expression, and tumor regression. These findings highlight LSD1 inhibition as a promising immunoepigenetic strategy to remodel the TME and improve the efficacy of immune checkpoint blockade in EBV-associated lymphomas. The online version contains supplementary material available at 10.1186/s12964-025-02614-0.
Case Report: Rare pulmonary infection and cytomegalovirus retinitis revealed a case of lymphoma.
Recurrent cytomegalovirus retinitis (CMVR) and rare opportunistic pulmonary infections may be the initial manifestations of underlying immunodeficiency caused by occult hematologic malignancy. Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified (EBV+DLBCL-NOS) is an aggressive lymphoma associated with immune dysfunction, predisposing patients to severe opportunistic infections, including CMVR. However, pulmonary co-infection with Tropheryma whipplei and Penicillium digitatum has not been previously described as a presenting feature of EBV+ DLBCL-NOS. A 66-year-old male presented with blurred vision and was diagnosed with CMVR, with profoundly low CD4+ T-cell counts (102 cells/μL) and high cytomegalovirus (CMV) DNA levels in blood and aqueous humor. He initially responded to ganciclovir, but CMVR recurred five months later, accompanied by new pulmonary nodules. Despite negative conventional microbiological tests, metagenomic next-generation sequencing (mNGS) of bronchoalveolar lavage fluid identified co-infection with Tropheryma whipplei and P. digitatum. Broad-spectrum antimicrobial therapy led to partial clinical improvement, but pulmonary lesions persisted. PET-CT revealed hypermetabolic lung and lymph node lesions, and subsequent lung biopsy confirmed EBV+ DLBCL-NOS. The patient's progressive immunodeficiency, recurrent CMVR, and refractory pulmonary infection were ultimately attributed to underlying lymphoma. This case highlights that severe, unexplained immunodeficiency with recurrent CMVR and rare opportunistic pulmonary infections should prompt a high index of suspicion for underlying hematologic malignancy. mNGS and PET-CT are critical tools in the diagnostic workup, but definitive diagnosis relies on histopathological confirmation. Early recognition of such presentations can prevent delays in diagnosing aggressive lymphomas.
Low hemoglobin as a novel prognostic biomarker in EBV-positive diffuse large B-cell lymphoma patients: a clinical feature analysis of 99 cases from Zhejiang, Southeast China.
Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV+DLBCL) is a rare and clinically aggressive subtype of DLBCL, distinguished by its notably unfavorable prognosis. The clinical characteristics of this entity remain insufficiently characterized in the Chinese population. This study retrospectively analyzed 99 cases of EBV+DLBCL with available clinical data from Zhejiang Province, southeastern China. We comprehensively characterized the clinicopathological features of these patients and performed both univariate and multivariate survival analyses to identify independent prognostic factors. Specifically, 76.7% of patients presented with an Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2, 75.8% demonstrated extranodal disease involvement, and 47.5% exhibited B symptoms. Immunophenotypic analysis utilizing the Hans algorithm classified 82.8% (82/99) of cases as non-germinal center B-cell-like (non-GCB) cell-of-origin (COO). The overall survival (OS) rate was 45.4%, while the progression-free survival (PFS) rate was 30.3%. The majority of patients (71.7%, 71/99) received R-CHOP-type immunochemotherapy regimens. Both univariate and multivariate analyses identified R-CHOP-type therapy as a significant independent protective factor for both OS (P < 0.001) and PFS (P = 0.001). Multivariate analysis further revealed that hemoglobin (Hb) levels < 90 g/L, indicative of anemia, represented a potential strong adverse prognostic factor for OS, with moderate to severe anemia emerging as a clinically relevant predictor of poorer treatment outcomes. These findings underscore that EBV+DLBCL constitutes a clinically distinct lymphoma subtype associated with suboptimal outcomes under current chemoimmunotherapy. Notably, readily monitored Hb levels may serve as a practical prognostic biomarker for risk stratification in this patient population. The online version contains supplementary material available at 10.1007/s00277-026-06912-6.
Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma Presenting as Pyrexia of Unknown Origin Complicated by Paraneoplastic Neurological Syndrome.
Chikungunya virus (CHIKV) infection is an arboviral disease transmitted by Aedes mosquitoes, typically presenting with fever, rash, and polyarthralgia. Neurological complications such as meningitis are rare and more often seen in neonates and immunocompromised individuals. Hepatic involvement is also uncommon, with only a few reports describing significant hepatitis in the absence of other risk factors. We report the case of a 68-year-old male, previously healthy with no comorbidities, who presented with acute febrile illness followed by severe headache, neck stiffness, and altered sensorium. Laboratory investigations revealed elevated transaminases, and cerebrospinal fluid analysis was consistent with viral meningitis. Serology confirmed CHIKV infection (immunoglobulin M enzyme-linked immunosorbent assay positive). Neuroimaging was unremarkable. The patient was managed with supportive care, intravenous fluids, and close neurological monitoring. Liver function normalized gradually over 2 weeks, and neurological recovery was complete by discharge. This case highlights the rare dual presentation of Chikungunya meningitis and hepatitis in an elderly patient without underlying comorbidities, underscoring the need for clinicians in endemic areas to consider CHIKV in the differential diagnosis of viral meningitis with hepatic dysfunction. RésuméLe virus Chikungunya (CHIKV) est un arbovirus transmis par les moustiques Aedes, se manifestant généralement par une fièvre, une éruption cutanée et des polyarthralgies. Les complications neurologiques, telles que la méningite, demeurent rares et surviennent plus fréquemment chez les nouveau-nés et les personnes immunodéprimées. L’atteinte hépatique est également inhabituelle, avec seulement quelques cas décrits de véritable hépatite en l’absence d’autres facteurs de risque. Nous rapportons le cas d’un homme de 68 ans, auparavant en bonne santé et sans comorbidités, présentant un syndrome fébrile aigu suivi de céphalées intenses, raideur de la nuque et altération de la conscience. Les examens biologiques ont montré une élévation des transaminases, et l’analyse du liquide céphalorachidien indiquait une méningite virale. La sérologie a confirmé l’infection par le CHIKV (test ELISA IgM positif). L’imagerie cérébrale était normale. Le patient a été pris en charge de manière symptomatique avec hydratation intraveineuse et surveillance neurologique rapprochée. La fonction hépatique s’est normalisée progressivement en deux semaines, et la récupération neurologique a été complète au moment de la sortie. Ce cas illustre la présentation rare d’une méningite associée à une hépatite due au Chikungunya chez un patient âgé sans comorbidités, soulignant l’importance, dans les zones endémiques, d’évoquer le CHIKV devant un tableau de méningite virale accompagnée d’une dysfonction hépatique.
Publicações recentes
Long noncoding RNA ADEI/miR-93-3p/STAT3 axis promotes Epstein-Barr virus-positive diffuse large B-cell lymphoma progression and immune evasion through regulating the PD-1/PD-L1 checkpoint.
Case Report: Rare pulmonary infection and cytomegalovirus retinitis revealed a case of lymphoma.
Low hemoglobin as a novel prognostic biomarker in EBV-positive diffuse large B-cell lymphoma patients: a clinical feature analysis of 99 cases from Zhejiang, Southeast China.
Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma Presenting as Pyrexia of Unknown Origin Complicated by Paraneoplastic Neurological Syndrome.
Characteristics and prognosis of Epstein Barr virus-positive diffuse large B-cell lymphoma: a retrospective, single-center study.
📚 EuropePMC125 artigos no totalmostrando 115
Long noncoding RNA ADEI/miR-93-3p/STAT3 axis promotes Epstein-Barr virus-positive diffuse large B-cell lymphoma progression and immune evasion through regulating the PD-1/PD-L1 checkpoint.
Cell death & diseaseCase Report: Rare pulmonary infection and cytomegalovirus retinitis revealed a case of lymphoma.
Frontiers in medicineLow hemoglobin as a novel prognostic biomarker in EBV-positive diffuse large B-cell lymphoma patients: a clinical feature analysis of 99 cases from Zhejiang, Southeast China.
Annals of hematologyEpstein-Barr Virus-positive Diffuse Large B-cell Lymphoma Presenting as Pyrexia of Unknown Origin Complicated by Paraneoplastic Neurological Syndrome.
Annals of African medicineCharacteristics and prognosis of Epstein Barr virus-positive diffuse large B-cell lymphoma: a retrospective, single-center study.
Hematology (Amsterdam, Netherlands)Breast Implant-Associated Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma.
Case reports in hematologyUnmasking Epstein-Barr Virus (EBV)-Positive Large B-Cell Lymphoma as an Underlying Trigger in a Post-COVID Hemophagocytic Lymphohistiocytosis Case.
CureusBilateral Breast Implant-Associated Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: A Case Report and Literature Review.
Annals of plastic surgeryORY1001 enhances anti-tumor immunity via CXCL10-mediated macrophage modulation in EBV-positive DLBCL.
Cell communication and signaling : CCSUlcerative Necrobiosis Lipoidica in the Setting of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma and Glucose-6-Phosphate Dehydrogenase Deficiency.
CureusSuccessful Use of Haploidentical HSCT in a Child With Schimke Immuno-Osseous Dysplasia Who Developed PTLD After Kidney Transplantation.
Pediatric transplantationClinical characteristics and outcomes in Epstein-Barr virus-positive diffuse large B-cell lymphoma: a multicenter retrospective study.
Turkish journal of medical sciences[Late-onset Epstein-Barr virus-positive diffuse large B-cell lymphoma at the same site after treatment of extranodal NK/T-cell lymphoma].
[Rinsho ketsueki] The Japanese journal of clinical hematology[Chinese expert consensus on the diagnosis and management of Epstein-Barr virus positive diffuse large B cell lymphoma (2025)].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiPeripheral EBV antigen-specific T cell is dysfunctional in Epstein-Barr virus positive diffuse large B-cell lymphoma.
BMC cancerSpontaneous remission of Epstein-Barr virus positive diffuse large B-cell lymphoma after relapse post axicabtagene ciloleucel chimeric antigen receptor T-cell therapy.
Leukemia & lymphomaRecurrent Composite Lymphoma in an Elderly Man: A Case of Marginal Zone Lymphoma With Classic Hodgkin Features Treated With Brentuximab and Immunotherapy.
CureusTumor-Associated Sympathetic Nerves Promote the Progression of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)Tiger-man Appearance in a Case of DLBCL.
Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaEBV-positive diffuse large B cell lymphoma secondary to activated phosphoinositide 3 kinase δ syndrome type 1 (APDS1): a case report and literature review.
Frontiers in immunologySpatial transcriptomics reveals tumor microenvironment heterogeneity in EBV positive diffuse large B cell lymphoma.
Scientific reportsEpstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma Arising in Ulcerative Colitis: An Instructive Case Report and Literature Review.
CureusA Rare Case of Systemic Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma With Hemophagocytic Lymphohistiocytosis in an Immunocompetent Young Man: Potential Diagnostic Pitfall and Therapeutic Challenge.
Journal of medical casesHemophagocytic lymphohistiocytosis in a patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
ImmunotherapyAlemtuzumab monotherapy for T-cell prolymphocytic leukemia: an observational study in Japan.
Journal of clinical and experimental hematopathology : JCEHA Newly Diagnosed Patient With Human Immunodeficiency Virus (HIV)-Associated Epstein-Barr Virus (EBV)-Positive Diffuse Large B-cell Lymphoma and Esophageal Candidiasis: A Case Report.
CureusSpontaneous Regression of Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma in an HIV-Positive Patient: A Case Report and Literature Review.
CureusLymphoproliferative disorder progressing after partial remission following immunosuppressive drugs withdrawal in a patient with rheumatoid arthritis.
Modern rheumatology case reportsThe biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma, NOS.
HeliyonEpstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma with Epidermotropism.
Annals of dermatologyComplete remission of aggressive Epstein-Barr virus-positive diffuse large B-cell lymphoma following withdrawal of tacrolimus and low-dose anticancer drugs.
EJHaemCutaneous Methotrexate-Related Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in a Patient with Granulomatous Cutaneous T-Cell Lymphoma: A Case Report and Literature Review.
Clinical, cosmetic and investigational dermatology[Epstein-Barr virus positive diffuse large B-cell lymphoma complicated with plasma cell myeloma: report of a case].
Zhonghua bing li xue za zhi = Chinese journal of pathologyA rare case of Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified, in a patient with ulcerative colitis.
Clinical journal of gastroenterologyEBV-Positive Diffuse Large B-Cell Lymphoma in Association with Polyurethane Textured Breast Implants: Case Report and Literature Overview.
Aesthetic plastic surgeryNecrotic lymphadenopathy in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
QJM : monthly journal of the Association of PhysiciansPrimary hepatic Epstein-Barr virus-positive diffuse large B-cell lymphoma associated with azathioprine immunosuppression: a case report.
Journal of medical case reportsA Rare Case of Metachronous Peripheral T-cell Non-Hodgkin Lymphoma Following Epstein-barr Virus-positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified.
Oman medical journalTET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients.
CancerEpstein-Barr virus-positive diffuse large B-cell lymphoma onset as familial hemophagocytic lymphohistiocytosis in an infant.
Pediatric blood & cancerPathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nationwide cohort: implications for clinical and epidemiological studies.
HaematologicaAngioimmunoblastic T-Cell Lymphoma: A Case Report.
CureusCircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.
Molecular cancerOnset of pulmonary Epstein-Barr virus-positive diffuse large B-cell lymphoma in a patient with silicosis.
Thoracic cancerEpstein-Barr virus-positive diffuse large B-cell lymphoma after frontline brentuximab vedotin treatment of classical Hodgkin lymphoma.
Annals of hematologyA case report of right ventricular outflow tract obstruction caused by B-cell lymphoma: a rare presentation in an adult patient with pulmonary atresia.
European heart journal. Case reportsA sporadic case of CTLA4 haploinsufficiency manifesting as Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Journal of clinical and experimental hematopathology : JCEHClinical and molecular features of Epstein-Barr virus-positive diffuse large B-cell lymphoma: Results in a multi-center trial.
Clinical and translational medicineSuccessful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report.
Anti-cancer drugsSecondary Hemophagocytic Lymphohistiocytosis With Epstein-Barr Virus-Associated Transformed Follicular Lymphoma: A Case Report and Literature Review.
Frontiers in oncologyEpstein-Barr virus positive diffuse large B-cell lymphoma transformed into angioimmunoblastic T-cell lymphoma after treatment.
Clinical case reportsCharacteristics of Central Nervous System (CNS) Involvement in Children With Non-Hodgkin's Lymphoma (NHL) and the Diagnostic Value of CSF Flow Cytometry in CNS Positive Disease.
Technology in cancer research & treatmentHemophagocytic lymphohistiocytosis associated with Epstein-Barr virus-positive diffuse large B-cell lymphoma, NOS of bone marrow-liver-spleen type: an autopsy case report.
Journal of clinical and experimental hematopathology : JCEHThe Incidence of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.
CancersEpstein-Barr virus-positive diffuse large B-cell lymphoma with human immunodeficiency virus mimicking complicated frontal sinusitis: A case report.
World journal of clinical casesCutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified: A systematic review and comparative analysis with Epstein-Barr virus-negative, leg type.
Journal of the American Academy of DermatologyMultiple cutaneous ulcers revealing a primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Clinical case reportsEBV Positivity and Programmed Death-ligand 1 Expression in Diffuse Large B-cell Lymphoma: A Systematic Review.
Anticancer researchT-cell lymphoma with a granulomatous lesion of the lungs after autologous hematopoietic stem cell transplantation for Epstein-Barr virus-positive diffuse large B-cell lymphoma: a unique rare case of metachronous B-cell and T-cell lymphoma.
Diagnostic pathology[Epstein-Barr virus positive diffuse large B-cell lymphoma in adolescents with sleep snoring as the first symptom: a case report].
Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgeryInfectious mononucleosis mimicking Epstein-Barr virus positive diffuse large B-cell lymphoma not otherwise specified.
International journal of hematologic oncologyClinicopathological analysis of neoplastic PD-L1-positive EBV+ diffuse large B cell lymphoma, not otherwise specified, in a Japanese cohort.
Virchows Archiv : an international journal of pathology[Analysis of Factors Influencing Clinical Efficacy of Rituximab on Patients with Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma].
Zhongguo shi yan xue ye xue za zhi[Persistent malnutrition caused by Nihonkaiense diphyllobothriasis diagnosed during treatment of malignant lymphoma].
[Rinsho ketsueki] The Japanese journal of clinical hematologyEpidermotropic Epstein-Barr virus-Positive Diffuse Large B-Cell Lymphoma: A Series of 3 Cases of a Very Unusual High-Grade Lymphoma.
The American Journal of dermatopathologySuccessful Rituximab Monotherapy in Advanced-stage, Epstein-Barr Virus-positive Diffuse Large B-Cell Lymphoma in an Adolescent With Systemic Juvenile Idiopathic Arthritis.
Journal of pediatric hematology/oncology[Composite adult T-cell leukemia/lymphoma and Epstein-Barr virus-positive diffuse large B-cell lymphoma].
[Rinsho ketsueki] The Japanese journal of clinical hematologyA phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.
Annals of hematologyA Rare, Yet Treatable Pancreatic Tumor: Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma.
The American journal of case reportsEpstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression.
OncoimmunologyEpstein-Barr virus-positive diffuse large B-cell lymphoma after sustained remission of T-cell prolymphocytic leukemia with alemtuzumab.
Leukemia & lymphomaImpact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-Virus positive diffuse large B cell lymphoma.
British journal of haematologyFatal Hypogammaglobulinemia 3 Years after Rituximab in a Patient with Immune Thrombocytopenia: An Underlying Genetic Predisposition?
Case reports in immunologypSTAT3 and MYC in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
The Malaysian journal of pathologyEpstein-Barr virus-positive diffuse large B cell lymphoma, not otherwise specified, carrying a t(19;22)(q13;q11) translocation.
Annals of hematologyPrimary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma (DLBCL) in a patient taking fingolimod.
Dermatology online journalExpression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion.
Pathology, research and practicePrimary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified, in a nonimmunocompromised young man: A case report.
Journal of cutaneous pathologyMultiple Brain Biopsies for Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma with Extensive Necrosis in a Posttransplant Patient.
World neurosurgeryB7-H4 is highly expressed in aggressive Epstein-Barr virus positive diffuse large B-cell lymphoma and inhibits apoptosis through upregulating Erk1/2 and Akt signalling pathways.
Infectious agents and cancer[Prevalence and clinico-pathological characteristics in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma in a high complexity hospital in Cali, Columbia].
Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de CitologiaThe tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.
European journal of haematology[Genetic Alterations Involving PD-L1/PD-L2 in Human Malignancies].
Gan to kagaku ryoho. Cancer & chemotherapyEpstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, in the Oral Cavity.
The Journal of craniofacial surgeryPrimary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma: a rare and aggressive cutaneous lymphoma.
CutisLOCALLY INVASIVE PHEOCHROMOCYTOMA COMBINED WITH PRIMARY MALIGNANT ADRENAL LYMPHOMA.
AACE clinical case reportsGenetic heterogeneity and mutational signature in Chinese Epstein-Barr virus-positive diffuse large B-cell lymphoma.
PloS oneDifferent prevalence and clinical outcome of Epstein-Barr virus positive diffuse large B-cell lymphoma between North American and non-Western populations.
Annals of translational medicineThe Diving Bell and the Butterfly Revisited: A Fatal Case of Locked-in Syndrome in a Man With Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.
Clinical medicine insights. Blood disordersOutcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression.
HaematologicaPediatric Pulmonary Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: A Case Report and Review of the Literature.
Case reports in pathologyEpstein-Barr virus positive diffuse large B-cell lymphoma presenting with vaginal sloughing and ulcerated skin nodule.
Journal of cutaneous pathologyEpstein-Barr virus positive diffuse large B cell lymphoma with G17V RHOA mutation arising from peripheral T cell lymphoma, not otherwise specified.
Annals of hematologyTocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Hematological oncologyEpstein-Barr virus-positive diffuse large B-cell lymphoma.
Proceedings (Baylor University. Medical Center)Epstein-Barr virus (EBV) provides survival factors to EBV+ diffuse large B-cell lymphoma (DLBCL) lines and modulates cytokine induced specific chemotaxis in EBV+ DLBCL.
ImmunologyFrequent downregulation of BTB and CNC homology 2 expression in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Cancer scienceSynchronous Microscopic Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma of the Adrenal and Lymphoplasmacytic Lymphoma: De Novo Disease or Transformation?
International journal of surgical pathologyEpstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Involving the Colon in a Patient With Ulcerative Pancolitis and Polymyositis on Long-Term Methotrexate Therapy.
Gastroenterology researchEpstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: Is It Different between Over and Under 50 Years of Age?
Asian Pacific journal of cancer prevention : APJCPEpstein-Barr virus-positive diffuse large B cell lymphoma arising from a chronic lymphocytic leukemia: Overlapping features with classical Hodgkin lymphoma.
Pathology internationalNext generation sequencing revealed DNA ligase IV deficiency in a "developmentally normal" patient with massive brain Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Clinical immunology (Orlando, Fla.)[RS3PE syndrome associated with senile Epstein-Barr virus-positive diffuse large B cell lymphoma of a patient with colon cancer].
[Rinsho ketsueki] The Japanese journal of clinical hematology[Clinicopathological features and prognositic analysis of Epstein-Barr virus- positive diffuse large B-cell lymphoma in elderly: 7 cases report and literatures review].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiPD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.
PloS oneEpstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a concise review and update.
Current opinion in oncologyEpstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis.
PloS oneEpstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age.
Scientific reportsAge cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?
OncotargetEpstein-Barr Virus-Positive Diffuse Large B cell Lymphoma in the Experience of a Tertiary Medical Center in Poland.
Archivum immunologiae et therapiae experimentalisEBV+ diffuse large B-cell lymphoma arising within atrial myxoma in Chinese immunocompetent patient.
International journal of clinical and experimental pathologyEpstein-Barr virus-positive diffuse large B-cell lymphoma following acute myeloid leukemia: a common clonal origin indicated by chromosomal translocation t(3;4)(p25;q21).
International journal of hematology[Updates on Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly].
Zhonghua bing li xue za zhi = Chinese journal of pathologyIntegrated copy number and gene expression profiling analysis of Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Genes, chromosomes & cancerEpstein-Barr virus-positive diffuse large B-cell lymphoma in children: a disease reminiscent of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly.
Human pathologyAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Linfoma B difuso de grandes células positivo para o vírus Epstein-Barr.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Linfoma B difuso de grandes células positivo para o vírus Epstein-Barr e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Ainda não achamos doenças com sintomas parecidos o suficiente.
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
Não, o padrão de herança familiar desta doença é classificado como não aplicável nos catálogos médicos. Ela se desenvolve de forma adquirida ao longo da vida e não é transmitida geneticamente aos filhos.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
4 fontes citadas no texto · 6 publicações do grafo RarasNet (PubMed) · 4 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (2026). Linfoma B difuso de grandes células positivo para o vírus Epstein-Barr. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/linfoma-b-difuso-de-grandes-celulas-positivo-para-o-virus-epstein-barr
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Linfoma B difuso de grandes células positivo para o vírus Epstein-Barr
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- Codificação WHO/SUS
- fonte: WHO ICD-10 / DATASUS
- CID-11 (futuro)
- fonte: WHO ICD-11
- NIH/GARD
- fonte: GARD (NIH)
- Dado público estruturado
- fonte: Wikidata
- Ensaios clínicos
- fonte: ClinicalTrials.gov
